The virus that caused the COVID-19 pandemic, SARS-CoV-2, has had a profound impact on cardiovascular healthcare. Patients having a history of cardiovascular disease are more likely to experience morbidity and mortality. The virus can harm the heart in both direct and indirect ways, causing clinical syndromes such as acute myocardial injury, myocarditis, acute coronary syndromes, heart failure, and arrhythmias, some of which can last for months after the original infection, resulting in long-term problems. Drug-drug and drug-disease interactions have an impact on the therapy of COVID-19-related cardiac problems. Furthermore, several COVID-19 treatment drugs can have negative cardiac consequences. Because the Renin-Angiotensin-Aldosterone System (RAAS) is involved in viral entry, it's important to evaluate the adverse effects of drugs that target this system. For optimal patient care and disease outcome, adequate information on COVID-19's unique cardiovascular manifestations and the guidelines established for their management is essential. The goal of this study is to look at the pathophysiology of SARS-CoV2 infection and related cardiac problems, as well as how to treat them. It also highlights the influence it has on individuals with pre-existing cardiac disorders, as well as long-term problems and heart-related side effects of COVID-19 drugs.